The scigen juggernaut keeps on rolling. Here's today's announcement that relates to the registration of their insulin product (SciLin) in Thailand. Pol
09:20, Monday, 14 November 2005
Sydney - Monday - November 14: (RWE Australian Business News) - SciGen Ltd (ASX code: SIE) has received a licence to market its insulin product SciLin in the Kingdom of Thailand. According to the World Health Organisation, more than 3.5 Million Thais are diagnosed with diabetes and a large number of the population remains undiagnosed. The insulin pharmaceutical market in Thailand is estimated to be $US15 million. This market is presently shared by two multinational companies. Preparations are under way for the launch of SciLin in Thailand early next year. SciLin is currently registered and sold by SciGen or its partners in India, Vietnam and Pakistan, and will soon be launched in the Philippines.
SIE Price at posting:
0.0¢ Sentiment: None Disclosure: Held
